Aegerion Pharmaceuticals (AEGR) has started a Phase 3 Trial in Japan to evaluate its Lomitapide treatment for cutting low-density lipoprotein ("bad") cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
HoFH is a rare genetic disease that harms the ability of the body to remove LDL-C cholesterol. Sufferers often develop premature and progressive atherosclerosis, a narrowing or blocking of the arteries.
The trial adds to a Phase III study that has been completed in the U.S. and other countries.
Last year, Aegerion received orphan drug designation in Japan for Lomitapide. (PR)